New caffeic acid derivatives in the treatment of myocardial infarction
- Field
- Therapeutic Chemicals
- Reference No.
- IP00594
Key Problem and Market Opportunity
- Myocardial infarction occurs when blood flow stops in a part of the heart causing damage to the heart muscle. It triggers a sequence of inflammatory reactions involving the infiltration, activation, apoptosis and clearance of neutrophils and macrophages. Timely resolution of inflammation and recovery of cardiac function is critical to reduce morbidity and mortality.
- The available anti-inflammatory drugs for the treatment of myocardial infarction are composed primarily of non-steroidal anti inflammatory drugs (NSAIDS) and glucocorticoids. However, these drugs possess severe side effects and provide unsatisfactory results in some pathologies.
- According to Market Data Forecast, the global cardiovascular therapeutic drugs market is worth USD 126.8 billion in 2016 and is projected to reach USD 141.38 billion by 2021 at a CAGR of 2.2%.